Holen Sie sich die Stockscreener-App
34.70
1.17%
-0.41
Handel nachbörslich:
34.70
Schlusskurs vom Vortag:
$35.11
Offen:
$34.86
24-Stunden-Volumen:
678.53K
Relative Volume:
1.20
Marktkapitalisierung:
$2.56B
Einnahmen:
$13.17M
Nettoeinkommen (Verlust:
$-199.06M
KGV:
-12.66
EPS:
-2.74
Netto-Cashflow:
$-156.53M
1W Leistung:
+3.77%
1M Leistung:
-1.81%
6M Leistung:
-21.51%
1J Leistung:
-12.99%
1-Tages-Spanne:
$32.26
$36.21
1-Wochen-Bereich:
$32.26
$36.21
52-Wochen-Spanne:
$26.74
$46.00
Xenon Pharmaceuticals Inc Stock (XENE) Company Profile
Firmenname
Xenon Pharmaceuticals Inc
Sektor
Branche
Telefon
(604) 484-3300
Adresse
200 - 3650 GILMORE WAY, BURNABY
Vergleichen Sie XENE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
XENE
Xenon Pharmaceuticals Inc
|
34.70 | 2.56B | 13.17M | -199.06M | -156.53M | -2.74 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Xenon Pharmaceuticals Inc Stock (XENE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-11 | Eingeleitet | Deutsche Bank | Buy |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-10-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-01-04 | Eingeleitet | Citigroup | Buy |
| 2023-12-08 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-10-24 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-04-25 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-12-14 | Eingeleitet | Goldman | Buy |
| 2022-12-12 | Eingeleitet | Cowen | Outperform |
| 2022-11-28 | Eingeleitet | Wells Fargo | Overweight |
| 2022-10-19 | Eingeleitet | Raymond James | Outperform |
| 2022-08-29 | Eingeleitet | BofA Securities | Buy |
| 2022-07-21 | Eingeleitet | JP Morgan | Overweight |
| 2021-10-28 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-10-02 | Eingeleitet | SVB Leerink | Outperform |
| 2020-07-21 | Eingeleitet | Needham | Buy |
| 2020-06-01 | Fortgesetzt | Jefferies | Buy |
| 2020-03-25 | Eingeleitet | Wedbush | Outperform |
| 2020-01-08 | Eingeleitet | William Blair | Outperform |
| 2019-09-20 | Eingeleitet | Guggenheim | Buy |
| 2018-08-08 | Bestätigt | Stifel | Buy |
| 2017-03-13 | Eingeleitet | Jefferies | Buy |
| 2016-10-21 | Eingeleitet | Stifel | Buy |
| 2016-09-26 | Eingeleitet | Guggenheim | Buy |
| 2016-04-14 | Bestätigt | Jefferies | Buy |
| 2015-10-30 | Fortgesetzt | Jefferies | Buy |
| 2014-12-02 | Eingeleitet | Canaccord Genuity | Buy |
Alle ansehen
Xenon Pharmaceuticals Inc Aktie (XENE) Neueste Nachrichten
When (XENE) Moves Investors should Listen - news.stocktradersdaily.com
The Goldman Sachs Group Has Lowered Expectations for Xenon Pharmaceuticals (NASDAQ:XENE) Stock Price - Defense World
Xenon- A Later Stage Story (NASDAQ:XENE) - Seeking Alpha
Xenon Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:XENE) - Defense World
Q1 EPS Forecast for Xenon Pharmaceuticals Raised by Analyst - Defense World
Xenon Pharmaceuticals: Undervalued Stock with Promising Catalysts and Growth Potential - TipRanks
StockNews.com Downgrades Xenon Pharmaceuticals (NASDAQ:XENE) to Sell - Defense World
Xenon Pharmaceuticals (NASDAQ:XENE) Stock Rating Lowered by StockNews.com - Defense World
JPMorgan Chase & Co. Increases Stock Holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
Prudential Financial Inc. Acquires 24,956 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
Raymond James Financial Inc. Buys New Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
Xenon Pharmaceuticals Looks Attractive Before Epilepsy Data (NASDAQ:XENE) - Seeking Alpha
Xenon Pharmaceuticals to Present Promising Azetukalner Data at AAN 2025 - TipRanks
Xenon Slides Ahead of San Diego Concference - Baystreet.ca
Xenon to Showcase Long-Term 36-Month Azetukalner Data at AAN 2025 - The Manila Times
Breakthrough Epilepsy Drug Shows Remarkable 3-Year Efficacy Data - Stock Titan
Investors Purchase Large Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE) - Defense World
Xenon Pharmaceuticals Enters Oversold Territory (XENE) - Nasdaq
Thrivent Financial for Lutherans Sells 12,394 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Consensus Recommendation of “Buy” by Analysts - Defense World
Teacher Retirement System of Texas Acquires 2,994 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
XENE stock touches 52-week low at $33.16 amid market shifts - Investing.com
11 Best Gene Therapy Stocks to Buy According to Analysts - Insider Monkey
StockNews.com Upgrades Xenon Pharmaceuticals (NASDAQ:XENE) to Hold - Defense World
Focal Epilepsy Market: Analysis of Epidemiology, Pipeline - openPR.com
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Bought by Swiss National Bank - Defense World
(XENE) Trading Advice - news.stocktradersdaily.com
Xenon Pharmaceuticals announces executive changes - MSN
Bank of New York Mellon Corp Sells 2,294 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
Xenon Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:XENE) - MarketBeat
What is William Blair’s Estimate for XENE Q1 Earnings? - Defense World
Xenon Pharmaceuticals at Stifel Forum: Strategic Advances in CNS By Investing.com - Investing.com Canada
Xenon Pharmaceuticals’ CCO Departure and Consultancy Role - MSN
(XENE) Trading Signals - Stock Traders Daily
Xenon Pharmaceuticals to Present at Stifel 2025 Virtual CNS Forum - TipRanks
Xenon to Present at Stifel 2025 Virtual CNS Forum - The Manila Times
Xenon Pharmaceuticals Inc. to Host Earnings Call - ACCESS Newswire
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Consensus Rating of “Buy” by Brokerages - Defense World
Traders Buy Large Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE) - The AM Reporter
Xenon Pharmaceuticals appoints PwC as new auditor - Investing.com
Xenon Pharmaceuticals appoints PwC as new auditor By Investing.com - Investing.com South Africa
New KCNQ2/3 activators disclosed in Xenon Pharmaceuticals patents - BioWorld Online
Q1 Earnings Forecast for XENE Issued By HC Wainwright - Defense World
Equities Analysts Offer Predictions for XENE Q1 Earnings - Defense World
(XENE) On The My Stocks Page - Stock Traders Daily
What is Leerink Partnrs’ Estimate for XENE Q1 Earnings? - Defense World
Xenon Pharmaceuticals (NASDAQ:XENE) Hits New 1-Year Low – Time to Sell? - Defense World
Xenon Pharmaceuticals (NASDAQ:XENE) Earns “Outperform” Rating from William Blair - Defense World
Xenon Q4 Loss Narrower Than Expected, Pipeline Development in Focus - MSN
Xenon Pharmaceuticals (NASDAQ:XENE) Issues Quarterly Earnings Results, Beats Estimates By $0.05 EPS - MarketBeat
HC Wainwright Has Pessimistic Outlook of XENE Q1 Earnings - MarketBeat
Finanzdaten der Xenon Pharmaceuticals Inc-Aktie (XENE)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.15%
4.32%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):